Freelite® Human Kappa Free kit for use on the SPAPLUS For in vitro diagnostic use Product code: LK016.L.S
Verification of Newly FDA-Approved Kappa and Lambda Free Light Chain Assays on a Previously Untested Platform
Freelite® Human Kappa Free kit For use on the Roche Cobas Integra® For in vitro diagnostic use Product Code: LK016.RI
![International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2008.307/MediaObjects/41375_2009_Article_BFleu2008307_Fig1_HTML.jpg)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia
![PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS) PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS)](https://www.researchgate.net/profile/Dirk-Larson/publication/7883288/figure/tbl2/AS:601807722127390@1520493550610/Absolute-Risk-of-Progression-of-MGUS-to-Myeloma-or-Related-Disorders-Based-on-the-Serum_Q320.jpg)
PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS)
![Cancers | Free Full-Text | Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil Cancers | Free Full-Text | Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil](https://www.mdpi.com/cancers/cancers-15-01605/article_deploy/html/images/cancers-15-01605-g001.png)
Cancers | Free Full-Text | Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil
![Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients | Leukemia Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2012.159/MediaObjects/41375_2013_Article_BFleu2012159_Fig1_HTML.jpg)
Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients | Leukemia
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma | Haematologica
Serum free light chain assays (Freelite®) are recommended by the NCCN Clinical Practice Guidelines in Oncology and the Internat
![Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis](https://www.degruyter.com/document/doi/10.1515/cclm-2015-0799/asset/graphic/j_cclm-2015-0799_fig_002.jpg)
Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis
![PDF) Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney diesease on haemolysis PDF) Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney diesease on haemolysis](https://www.researchgate.net/profile/Carel-Pretorius/publication/287483244/figure/tbl1/AS:669264314912777@1536576455670/FLC-assay-results-pre-and-post-haemodialysis_Q320.jpg)
PDF) Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney diesease on haemolysis
![Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance - ScienceDirect Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120531923-gr1.jpg)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance - ScienceDirect
![Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/97343738-f909-4e28-94e4-b624973cd798/hsr2113-fig-0001-m.jpg)
Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library
![Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c86c0fb5-0da8-451e-af81-d2ade967b08e/hsr2113-fig-0004-m.jpg)
Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library
![Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis](https://www.degruyter.com/document/doi/10.1515/cclm-2015-0799/asset/graphic/j_cclm-2015-0799_fig_001.jpg)